Company Profile

Quidel Corporation
Profile last edited on: 8/18/2023      CAGE: 0TH42      UEI: VNAKZRHYAUC7

Business Identifier: Rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic system
Year Founded
1979
First Award
2004
Latest Award
2004
Program Status
Inactive
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

9975 Summers Ridge Road
San Diego, CA 92121
   (858) 552-1100
   ir@quidel.com
   www.quidel.com
Location: Single
Congr. District: 52
County: San Diego

Public Profile

Quidel Corporation develops, manufactures and markets point-of-care (POC) rapid diagnostic tests for the detection and management of medical conditions and illnesses. Long since having outgrown SBIR eligibility, in June 2020, the firm received a major BARDA Grant to develop a point-of-care diagnostic assay that Includes COVID-19. The Company's products provide healthcare professionals and consumers with accurate and cost-effective diagnostic information at the POC. The Company sells its products to professionals for use in physician offices, hospitals, clinical laboratories and wellness screening centers. The Company provides rapid POC diagnostic tests under the brand names QuickVue, QuickVue+, QuickVue Advance, OvuQuick, Conceive, CARDS, RapidVue, BlueTest, Metra, QUS-2, UrinQuick, RapiMat and FemExam. The Company's rapid POC diagnostic tests, biochemical bone markers and ultrasonometer participate in the following medical and wellness categories: pregnancy, group A strep and influenza detection, metabolic bone markers, Helicobacter pylori, urinalysis, other infectious disease products, ovulation QUS-2, bacterial vaginosis and other products.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
500+
Revenue Range
Over 50M
VC funded?
Yes
Public/Private
Publicly Traded
Stock Info
NASDAQ : QDEL
IP Holdings
100-149

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2004 1 NIH $133,750
Project Title: A High Accuracy Point-of-Care Chlamydia trachomatis Test

Key People / Management

  Caren L Mason -- President

  Michael K Helms

Company News

There are no news available.